Hundreds of thousands of patients are diagnosed each year with metastatic cancer. More than 70,000 patients in the US alone are diagnosed with CUP, and the primary origin of the metastasis is never identified1. Patients undergo a wide range of costly, time-consuming, and inefficient tests to identify the primary site of origin, often to no avail2. Effective treatment of these patients relies on accurate identification of tumor origin, and it is clear that a better diagnostic method is needed2.

miRview™ mets is a cutting-edge, microRNA-based molecular diagnostic tool that identifies the tissue-of-origin of metastatic tumors. The test offers:

• Accuracy
• Efficiency
• Validity
• Simple interpretation
• Quantitative analysis
• Objective results
• Cutting-edge molecular biology

1. Blaszyk H, Hartmann A, Bjornsson J. Cancer of unknown primary: clinicopathologic correlations. APMIS. 2003;111(12):1089-1094.
2. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer.
   Cancer. 2004;100(9):1776-1785.